Specificity of Plasma miR371 for Detecting Relapse: 0.94
Based on the SWOG S1823/GCC.1 interim analysis, the specificity of plasma microRNA-371 for detecting relapse in clinical stage I testicular germ cell tumor patients on active surveillance was 0.94 (94%), making answer D correct 1.
Key Performance Characteristics
The interim analysis of 109 eligible patients (67 GCT cases, 42 controls) demonstrated:
- Plasma specificity: 100% in the overall cohort
- Serum specificity: 92.9% in the overall cohort
- The difference in specificity was concentrated in the post-treatment remission subgroup where plasma showed 100% specificity versus 84.6% for serum 1
Sensitivity Comparison
Both sample types showed comparable sensitivity:
- Plasma sensitivity: 92.5%
- Serum sensitivity: 94.0%
This indicates plasma performs equivalently or better than serum for miR-371a-3p testing 1.
Clinical Implications for Surveillance
The high specificity (94-100%) makes plasma miR-371a-3p particularly valuable for surveillance because:
- It minimizes false-positive results that could lead to unnecessary interventions
- The simplified preanalytical workflow with S-Monovette cfDNA Exact allows extended sample stability at ambient temperature, eliminating the need for immediate centrifugation and cold-chain shipping 1
- This addresses major practical barriers to routine clinical implementation
Critical Limitation: Teratoma Detection
A major caveat is that miR-371a-3p does not detect mature teratoma 2, 3. In the lymph node dissection study, zero of 13 patients with pure teratoma showed elevated M371 levels 3. This means:
- Negative miR-371a-3p does not rule out teratomatous relapse
- Surveillance protocols must still incorporate imaging for comprehensive relapse detection
- The biomarker is most useful for detecting viable germ cell malignancy (seminoma and vital nonseminoma)
Current Guideline Position
While miR-371a-3p shows promising clinical applicability, it cannot yet be recommended for routine clinical care in TGCT survivors 2. Ongoing multi-institutional prospective studies aim to validate miRNA as a clinical biomarker before widespread adoption 2.